ReviewNature reviews. Rheumatology2025
Cutaneous lupus erythematosus - from pathogenesis to targeted therapy.
Review in Nature reviews. Rheumatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Leprosy masquerading as systemic lupus erythematosus: a case report and systematic review of the literature.Advances in rheumatology (London, England) · 2026Pooled it
- Microarray Gene Expression Analysis of Lesional Skin in Canine Vesicular Cutaneous Lupus Erythematosus (VCLE).Veterinary dermatology · 2026Article
- LC-OCT for Cutaneous Lupus Erythematosus: Characterization Across Disease Subtypes and Differentiation From Rosacea.Experimental dermatology · 2026Observational
- Haemorrhagic Plaque-Like Lesion in SLE in a Young Girl.Indian journal of pediatrics · 2026Article
- CD8MedComm · 2026Review
- Upregulated GLUT1 expression correlates with type I interferon activity and disease severity in cutaneous lupus erythematosus.Journal of translational autoimmunity · 2026Article
- A refined blueprint for human skin.Nature genetics · 2026Article
- Facial discoid lupus erythematosus complicated by aFrontiers in medicine · 2026Article
- Atypical Facial and Scalp Lupus Erythematosus Tumidus: Diagnostic Challenges from Long-Term Misdiagnosis and Conflicting Histopathology.Clinical, cosmetic and investigational dermatology · 2026Article
- Beyond barrier function: keratinocytes as orchestrators of humoral immunity.Immunity & inflammation · 2026Article
- Therapeutic Approaches for Cutaneous Lupus Erythematosus: a Changing Landscape of Clinical Trials.Journal of inflammation research · 2026Review
- Cuproptosis: A Potential Target for the Treatment of Systemic Lupus Erythematosus.Journal of inflammation research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Cutaneous lupus erythematosus (CLE) is a complex inflammatory skin disease that presents either in isolation or as a frequent manifestation of systemic lupus erythematosus (SLE). CLE subtypes show clinical heterogeneity and varying associations with SLE. Histologically, CLE is characterized by interface dermatitis, a reaction pattern that involves immune-cell infiltration of the dermo-epidermal junction. In-depth characterization of both non-lesional and lesional lupus skin has reshaped our understanding of pathogenesis. Non-lesional and lesional lupus skin exhibits early and chronic upregulation of type I interferons, which drive photosensitivity, myeloid-cell recruitment and amplification of cytokine responses in both immune and non-immune cells. This detailed understanding of CLE biology has enabled the development of targeted therapies. Ongoing research to identify key pathogenic mechanisms will create opportunities for prevention of CLE and CLE-to-SLE transition.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.